Drugs Made In America Acquisition II Corp. Rights represent a class of financial instruments associated with a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. This blank check company was formed to pursue a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination primarily within the pharmaceutical sector. The rights entitle holders to receive a fractional ordinary share upon consummation of the company's initial business combination. The entity focuses on addressing supply chain risks in the U.S. pharmaceutical industry by investing in companies involved in on-shoring advanced domestic manufacturing technologies for critical drugs. These rights began separate trading on the Nasdaq Global Market under the symbol corresponding to the rights, following the company's $500 million initial public offering of units that included ordinary shares and related rights. The rights play a role in providing investors with opportunities linked to the company’s planned business combination in the pharmaceutical space.